Please login to the form below
28
Revenue 2017Ibrance
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Ibrance was produced by Pfizer.
Pfizer expands low-cost medicine and vaccine programme to include off-patent products
in the US or EU, including COVID-19 treatment Paxlovid and breast cancer drug Ibrance.
Putting the ovation into innovation: trends from ESMO
The first approved CDK4/6 inhibitor, palbociclib (IBRANCE) showcased the most comprehensive first-line comparative real-world study at ESMO Breast 2022, where it demonstrated a significant overall survival (OS) benefit
Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
Outside the US, CDK4/6 inhibitor Ibrance was also up by 21%, while sales of tyrosine kinase inhibitor (TKI) Inlyta also increased by 29% globally following increased adoption in the US ... In addition, sales of Ibrance in the US dropped by 7% as the
Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
ARV-471 is also being studied in a phase 1b combination study alongside Pfizer’s blockbuster CDK4/6 inhibitor Ibrance (palbociclib). ... Looking ahead to 2022, the two companies also expect to begin phase 3 studies across different lines of therapy in
Novartis' Kisqali shows long-term improvements in breast cancer patients
Kisqali’s main rival in the HR-positive/HER2-positive breast cancer setting is Pfizer’s market leader Ibrance (palbociclib).
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
Origins - The Patient Focused Specialists
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
